E

What science tells us about future directions in lung cancer

What we can learn from scientific talks at WCLC in order to improve clinical development

September 13, 2023
E

Kicking KRAS to the kerb

Review of new KRAS inhibitor studies including G12C and G12D

September 11, 2023
E

WCLC23 – SCLC highlights and lowlights

Seeing the wood from the trees in ES-SCLC developments

September 11, 2023
E

The ADC merry-go-round

Part 2 of our WCLC 2023 Previews

August 22, 2023
E

What’s hot in lung cancer?

Preview - Wwat to watch for at WCLC23

July 27, 2023
E

Digging deep for answers

Finding rare thistles in the fields

July 19, 2023
E

New directions in small cell lung cancer

A look at promising new approaches in SCLC

August 12, 2022
E

Going beyond sotorasib and adagrasib

On fast followers and novel G12C combinations

August 8, 2022
E

The road to Damascus is paved with good intentions

Trials and tribulations associated with KRAS plus IO combos

August 8, 2022
E

Are we overpromising with protein degraders?

Going beyond small molecule inhibitors to degrading various intractable targets

July 19, 2022
E

What do the Konami code and targeting KRAS have in common?

A rock around the KRAS clock

July 12, 2022
E

An alternative perspective on TIGIT

What can we learn from IO trials in lung cancer to help us evaluate TIGIT's prospects?

June 23, 2022
E

Are there challenging times ahead for KRAS inhibitor combinations?

A lion roar or whimper at the prospect of KRASi plus IO trials?

April 5, 2022
E

Standing out from the crowd in lung cancer

Highlights from WCLC Day 1

September 9, 2021
E

WCLC21 Preview of key data to watch out for

What's hot at WCLC21?

August 19, 2021
E

Emerging developments and trends in advanced lung cancer

Gems from the WCLC20 poster hall which may make an impact

February 9, 2021
E

A look at the exon 20 landscape in lung cancer

A look at the exon 20 insertion landscape - all to play for!

February 4, 2021
E

What happens when genomics, KRAS, and IO converge in lung cancer?

Genomic analysis in IO trials is on the increase - what happens when PD-1 and KRAS collide?

February 2, 2021
E

A critical look at the Amgen sotorasib data in KRAS G12C mutated lung cancers

Discussion of the Amgen sotorasib data presented at WCLC20 in Singapore

February 1, 2021
E

How will AI impact oncology R&D?

Some intriguing convergence from two recent conferences offers new insights from an AI perspective

January 28, 2021
E

AACR Preview 2 – Pathways to Success in Targeted Therapies

A look at a wide array of targets, modalities, new agents and companies through the lens of targeted therapies

April 16, 2020
E

The many faces of lung cancer

WCLC 2019 Review – Part 3 - Targeted Therapy Highlights excluding KRASi

September 12, 2019
E

New developments in immunotherapy from WCLC19

Summary of IO highlights and lowlights from WCLC 2019

September 10, 2019
E

Targeting KRAS – Highlights from WCLC 2019

Barcelona – Gosh, what a weekend chock full of lung cancer data at the World Congress on Lung Cancer…

September 9, 2019
E
AMG 596 EGFRvIII BiTE

A look at Amgen’s early oncology pipeline

Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?

July 18, 2019
E

An update on key SCLC trials

A look at the CheckMate-331 and CheckMate-451 study and other SCLC trials

October 12, 2018
E

WCLC2018 Roundup of key lung cancer data

After the WCLC2018 preview, what does the data actually teach us? A round up and commentary on 16 key trials

September 25, 2018
E

Preview of WCLC 2018 – what’s new in lung cancer?

What to watch out for at WCLC2018 in Toronto later this month

September 6, 2018